The impact of lifecourse socio-economic position and individual social mobility on breast cancer risk.

Breast cancer Lifecourse socio-economic position Prospective cohorts Social mobility

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
23 Nov 2020
Historique:
received: 22 06 2020
accepted: 17 11 2020
entrez: 24 11 2020
pubmed: 25 11 2020
medline: 13 5 2021
Statut: epublish

Résumé

Women with an advantaged socioeconomic position (SEP) have a higher risk of developing breast cancer (BC). The reasons for this association do not seem to be limited to reproductive factors and remain to be understood. We aimed to investigate the impact of lifecourse SEP from childhood and social mobility on the risk of BC considering a broad set of potential mediators. We used a discovery-replication strategy in two European prospective cohorts, E3N (N = 83,436) and EPIC-Italy (N = 20,530). In E3N, 7877 women were diagnosed with BC during a median 24.4 years of follow-up, while in EPIC-Italy, 893 BC cases were diagnosed within 15.1 years. Hazard ratios (HR) were estimated using Cox proportional hazard models on imputed data. In E3N, women with higher education had a higher risk of BC (HR [95%CI] = 1.21 [1.12, 1.30]). This association was attenuated by adjusting for reproductive factors, in particular age at first childbirth (HR[95%CI] = 1.13 [1.04, 1.22]). Health behaviours, anthropometric variables, and BC screening had a weaker effect on the association. Women who remained in a stable advantaged SEP had a higher risk of BC (HR [95%CI] = 1.24 [1.07; 1.43]) attenuated after adjustment for potential mediators (HR [95%CI] = 1.13 [0.98; 1.31]). These results were replicated in EPIC-Italy. These results confirm the important role of reproductive factors in the social gradient in BC risk, which does not appear to be fully explained by the large set of potential mediators, including cancer screening, suggesting that further research is needed to identify additional mechanisms.

Sections du résumé

BACKGROUND BACKGROUND
Women with an advantaged socioeconomic position (SEP) have a higher risk of developing breast cancer (BC). The reasons for this association do not seem to be limited to reproductive factors and remain to be understood. We aimed to investigate the impact of lifecourse SEP from childhood and social mobility on the risk of BC considering a broad set of potential mediators.
METHODS METHODS
We used a discovery-replication strategy in two European prospective cohorts, E3N (N = 83,436) and EPIC-Italy (N = 20,530). In E3N, 7877 women were diagnosed with BC during a median 24.4 years of follow-up, while in EPIC-Italy, 893 BC cases were diagnosed within 15.1 years. Hazard ratios (HR) were estimated using Cox proportional hazard models on imputed data.
RESULTS RESULTS
In E3N, women with higher education had a higher risk of BC (HR [95%CI] = 1.21 [1.12, 1.30]). This association was attenuated by adjusting for reproductive factors, in particular age at first childbirth (HR[95%CI] = 1.13 [1.04, 1.22]). Health behaviours, anthropometric variables, and BC screening had a weaker effect on the association. Women who remained in a stable advantaged SEP had a higher risk of BC (HR [95%CI] = 1.24 [1.07; 1.43]) attenuated after adjustment for potential mediators (HR [95%CI] = 1.13 [0.98; 1.31]). These results were replicated in EPIC-Italy.
CONCLUSIONS CONCLUSIONS
These results confirm the important role of reproductive factors in the social gradient in BC risk, which does not appear to be fully explained by the large set of potential mediators, including cancer screening, suggesting that further research is needed to identify additional mechanisms.

Identifiants

pubmed: 33228587
doi: 10.1186/s12885-020-07648-w
pii: 10.1186/s12885-020-07648-w
pmc: PMC7684912
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1138

Subventions

Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom
Organisme : Institut National Du Cancer
ID : SHSESP 2017-130

Références

BMC Pediatr. 2015 Sep 21;15:129
pubmed: 26391227
J Epidemiol Community Health. 2013 Jan;67(1):6-13
pubmed: 22826293
J Nutr. 2011 Aug;141(8):1552-8
pubmed: 21628636
Tumori. 2003 Nov-Dec;89(6):586-93
pubmed: 14870823
Int J Public Health. 2018 Jan;63(1):93-103
pubmed: 29063122
Eur J Cancer. 2008 Sep;44(14):1996-2002
pubmed: 18701275
PLoS One. 2013 Aug 28;8(8):e72460
pubmed: 24015247
Cancer Epidemiol. 2011 Oct;35(5):438-41
pubmed: 21227766
Dan Med J. 2014 Oct;61(10):B4922
pubmed: 25283627
Soc Sci Med. 2003 Apr;56(7):1397-410
pubmed: 12614692
PLoS One. 2017 May 30;12(5):e0178071
pubmed: 28557991
Prev Med. 2018 Aug;113:15-31
pubmed: 29752959
Int J Cancer. 2008 Jan 1;122(1):165-9
pubmed: 17708572
Endocr Relat Cancer. 2005 Dec;12(4):1071-82
pubmed: 16322344
Am J Epidemiol. 2011 Jan 1;173(1):26-37
pubmed: 21084553
Soc Forces. 2013;92(1):1-24
pubmed: 25506089
Eur J Public Health. 2016 Oct;26(5):804-813
pubmed: 27221607
Int J Cancer. 2004 Sep 1;111(3):451-6
pubmed: 15221976
Breast Cancer Res Treat. 1982;2(1):5-73
pubmed: 6216933
Ann Hum Biol. 2000 Jul-Aug;27(4):407-21
pubmed: 10942348
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2591-7
pubmed: 16284383
Am J Ind Med. 2011 Jul;54(7):499-509
pubmed: 21472744
Int J Epidemiol. 2015 Jun;44(3):801-9
pubmed: 25212479
IARC Sci Publ. 1997;(138):285-308
pubmed: 9353670
Am J Epidemiol. 1997 Feb 15;145(4):366-72
pubmed: 9054241
Int J Epidemiol. 2014 Oct;43(5):1542-62
pubmed: 24771324
Breast Cancer Res Treat. 2014 Jun;145(3):567-79
pubmed: 24820413
J Aging Health. 2012 Mar;24(2):323-44
pubmed: 21956096
Am J Epidemiol. 2000 Nov 15;152(10):950-64
pubmed: 11092437
Int J Public Health. 2018 Sep;63(7):799-810
pubmed: 29774377
Public Health Nutr. 2003 Jun;6(4):407-13
pubmed: 12795830
Ann Occup Environ Med. 2019 Aug 14;31:e18
pubmed: 31620295
BMC Cancer. 2010 Feb 09;10:35
pubmed: 20144221
Breast Cancer Res. 2012 Jan 06;14(1):R5
pubmed: 22225950

Auteurs

Eloïse Berger (E)

UMR LEASP, Université de Toulouse III, UPS, Inserm, Toulouse, France. eloise.berger@univ-tlse3.fr.

Noële Maitre (N)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.

Francesca Romana Mancini (F)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.

Laura Baglietto (L)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Vittorio Perduca (V)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.
Université de Paris, CNRS, MAP5 UMR 8145, F-75006, Paris, France.

Hélène Colineaux (H)

UMR LEASP, Université de Toulouse III, UPS, Inserm, Toulouse, France.
Epidemiology Department, Toulouse Teaching Hospital, Toulouse, France.

Sabina Sieri (S)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Salvatore Panico (S)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provicial Health Authority (ASP) Ragusa, Ragusa, Italy.

Paolo Vineis (P)

Department of Epidemiology and Biostatistics, Imperial College London, MRC-PHE Centre for Environment and Health, School of Public Health, London, UK.
Italian Institute for Genomic Medicine, Torino, Italy.

Marie-Christine Boutron-Ruault (MC)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.

Gianluca Severi (G)

CESP, Faculté de Médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gustave Roussy, F-94805, Villejuif, France.
Department of Statistics, Computer Science and Applications "G. Parenti" (DISIA), University of Florence, Florence, Italy.

Raphaële Castagné (R)

UMR LEASP, Université de Toulouse III, UPS, Inserm, Toulouse, France.

Cyrille Delpierre (C)

UMR LEASP, Université de Toulouse III, UPS, Inserm, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH